JP2017515845A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515845A5 JP2017515845A5 JP2016567507A JP2016567507A JP2017515845A5 JP 2017515845 A5 JP2017515845 A5 JP 2017515845A5 JP 2016567507 A JP2016567507 A JP 2016567507A JP 2016567507 A JP2016567507 A JP 2016567507A JP 2017515845 A5 JP2017515845 A5 JP 2017515845A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dihydro
- carboxamide
- oxo
- triazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 11
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 10
- 230000035876 healing Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000010392 Bone Fractures Diseases 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 7
- 206010017076 Fracture Diseases 0.000 claims description 7
- 230000004761 fibrosis Effects 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 201000001474 proteinuria Diseases 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000006529 (C3-C6) alkyl group Chemical group 0.000 claims description 2
- MOKGJPFJPBCJGY-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-5-methyltriazole-4-carboxamide Chemical compound ClC1=C(C=CC(=C1)Cl)N1N=NC(=C1C)C(=O)NC=1C(N(N(C1C)C)C1=C(C=CC=C1)F)=O MOKGJPFJPBCJGY-UHFFFAOYSA-N 0.000 claims description 2
- DJCHYTWZRDUVHQ-UHFFFAOYSA-N 1-(2-chloro-4-cyclopropylphenyl)-N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-5-methyltriazole-4-carboxamide Chemical compound ClC1=C(C=CC(=C1)C1CC1)N1N=NC(=C1C)C(=O)NC=1C(N(N(C1C)C)C1CCCCC1)=O DJCHYTWZRDUVHQ-UHFFFAOYSA-N 0.000 claims description 2
- ACXUNKGGFBQCSH-UHFFFAOYSA-N 1-(2-chloro-4-cyclopropylphenyl)-N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-5-methyltriazole-4-carboxamide Chemical compound ClC1=C(C=CC(=C1)C1CC1)N1N=NC(=C1C)C(=O)NC=1C(N(N(C1C)C)C1=C(C=CC=C1)F)=O ACXUNKGGFBQCSH-UHFFFAOYSA-N 0.000 claims description 2
- DJCHYTWZRDUVHQ-HPRDVNIFSA-N 1-(2-chloro-4-cyclopropylphenyl)-N-[1-cyclohexyl-3-methyl-5-oxo-2-(trideuteriomethyl)pyrazol-4-yl]-5-methyltriazole-4-carboxamide Chemical compound [2H]C([2H])([2H])N1N(C2CCCCC2)C(=O)C(NC(=O)C2=C(C)N(N=N2)C2=CC=C(C=C2Cl)C2CC2)=C1C DJCHYTWZRDUVHQ-HPRDVNIFSA-N 0.000 claims description 2
- FODUFECSLYLXJO-UHFFFAOYSA-N 1-(2-chloro-4-methoxyphenyl)-N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-5-methyltriazole-4-carboxamide Chemical compound ClC1=C(C=CC(=C1)OC)N1N=NC(=C1C)C(=O)NC=1C(N(N(C1C)C)C1CCCCC1)=O FODUFECSLYLXJO-UHFFFAOYSA-N 0.000 claims description 2
- ISFJQKFPHDUWPE-UHFFFAOYSA-N 1-(4-chloro-2-cyclopropylphenyl)-N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-5-methyltriazole-4-carboxamide Chemical compound ClC1=CC(=C(C=C1)N1N=NC(=C1C)C(=O)NC=1C(N(N(C1C)C)C1CCCCC1)=O)C1CC1 ISFJQKFPHDUWPE-UHFFFAOYSA-N 0.000 claims description 2
- RZYISIGSIXJKBN-UHFFFAOYSA-N 1-(4-chloro-2-cyclopropylphenyl)-N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-5-methyltriazole-4-carboxamide Chemical compound ClC1=CC(=C(C=C1)N1N=NC(=C1C)C(=O)NC=1C(N(N(C1C)C)C1=C(C=CC=C1)F)=O)C1CC1 RZYISIGSIXJKBN-UHFFFAOYSA-N 0.000 claims description 2
- KSOXQHSQZWSLIA-UHFFFAOYSA-N 1-(4-chlorophenyl)-N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-5-methyltriazole-4-carboxamide Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1C)C(=O)NC=1C(N(N(C1C)C)C1CCCCC1)=O KSOXQHSQZWSLIA-UHFFFAOYSA-N 0.000 claims description 2
- SQLLXHARKNGURD-UHFFFAOYSA-N 1-(4-chlorophenyl)-N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-5-methyltriazole-4-carboxamide Chemical compound ClC1=CC=C(C=C1)N1N=NC(=C1C)C(=O)NC=1C(N(N(C1C)C)C1=C(C=CC=C1)F)=O SQLLXHARKNGURD-UHFFFAOYSA-N 0.000 claims description 2
- WXVDTPRGJZKZPF-UHFFFAOYSA-N 1-[2-chloro-4-(trifluoromethoxy)phenyl]-N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-5-methyltriazole-4-carboxamide Chemical compound ClC1=C(C=CC(=C1)OC(F)(F)F)N1N=NC(=C1C)C(=O)NC=1C(N(N(C1C)C)C1CCCCC1)=O WXVDTPRGJZKZPF-UHFFFAOYSA-N 0.000 claims description 2
- JMXMZZABLCOWIP-UHFFFAOYSA-N 1-[2-chloro-4-(trifluoromethoxy)phenyl]-N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-5-methyltriazole-4-carboxamide Chemical compound ClC1=C(C=CC(=C1)OC(F)(F)F)N1N=NC(=C1C)C(=O)NC=1C(N(N(C1C)C)C1=C(C=CC=C1)F)=O JMXMZZABLCOWIP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 2
- LVMFPVUIWOOJNY-UHFFFAOYSA-N N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-1-(2,4-dichlorophenyl)-5-methyltriazole-4-carboxamide Chemical compound C1(CCCCC1)N1N(C(=C(C1=O)NC(=O)C=1N=NN(C1C)C1=C(C=C(C=C1)Cl)Cl)C)C LVMFPVUIWOOJNY-UHFFFAOYSA-N 0.000 claims description 2
- LEXOBXPBMTWDHU-UHFFFAOYSA-N N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-1-(2-cyclopropyl-4-fluorophenyl)-5-methyltriazole-4-carboxamide Chemical compound C1(CCCCC1)N1N(C(=C(C1=O)NC(=O)C=1N=NN(C1C)C1=C(C=C(C=C1)F)C1CC1)C)C LEXOBXPBMTWDHU-UHFFFAOYSA-N 0.000 claims description 2
- SMEJNAIKZQKEDP-UHFFFAOYSA-N N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-1-(4-methoxy-3-methylphenyl)-5-methyltriazole-4-carboxamide Chemical compound C1(CCCCC1)N1N(C(=C(C1=O)NC(=O)C=1N=NN(C1C)C1=CC(=C(C=C1)OC)C)C)C SMEJNAIKZQKEDP-UHFFFAOYSA-N 0.000 claims description 2
- NGQWUQYESZDKHI-UHFFFAOYSA-N N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-1-[4-methoxy-2-(trifluoromethyl)phenyl]-5-methyltriazole-4-carboxamide Chemical compound C1(CCCCC1)N1N(C(=C(C1=O)NC(=O)C=1N=NN(C1C)C1=C(C=C(C=C1)OC)C(F)(F)F)C)C NGQWUQYESZDKHI-UHFFFAOYSA-N 0.000 claims description 2
- NOVSDVCDYPGXAQ-UHFFFAOYSA-N N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-8-(trifluoromethoxy)-5,6-dihydro-4H-triazolo[1,5-a][1]benzazepine-3-carboxamide Chemical compound C1(CCCCC1)N1N(C(=C(C1=O)NC(=O)C=1N=NN2C1CCCC1=C2C=CC(=C1)OC(F)(F)F)C)C NOVSDVCDYPGXAQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000002785 azepinyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- -1 chloro, fluoro, cyclopropyl Chemical group 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- KLJDGTASMZJZDR-UHFFFAOYSA-N 2-cyclohexyl-1,5-dimethylpyrazol-3-one Chemical compound CN1C(C)=CC(=O)N1C1CCCCC1 KLJDGTASMZJZDR-UHFFFAOYSA-N 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WGVHNCAJPFIFCR-UHFFFAOYSA-N 5-methyl-1,2-dihydropyrazol-3-one Chemical compound CC1=CC(O)=NN1 WGVHNCAJPFIFCR-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- GPKSXWTVPBSUBX-UHFFFAOYSA-N N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-1-(4-methoxyphenyl)-5-methyltriazole-4-carboxamide Chemical compound C1(CCCCC1)N1N(C(=C(C1=O)NC(=O)C=1N=NN(C1C)C1=CC=C(C=C1)OC)C)C GPKSXWTVPBSUBX-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993046P | 2014-05-14 | 2014-05-14 | |
| EP14168319 | 2014-05-14 | ||
| US61/993,046 | 2014-05-14 | ||
| EP14168319.3 | 2014-05-14 | ||
| PCT/IB2015/001539 WO2015177646A1 (en) | 2014-05-14 | 2015-05-14 | Carboxamide derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515845A JP2017515845A (ja) | 2017-06-15 |
| JP2017515845A5 true JP2017515845A5 (enExample) | 2018-06-14 |
| JP6587637B2 JP6587637B2 (ja) | 2019-10-09 |
Family
ID=50735906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567507A Active JP6587637B2 (ja) | 2014-05-14 | 2015-05-14 | カルボキサミド誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9403833B2 (enExample) |
| EP (1) | EP3143014B1 (enExample) |
| JP (1) | JP6587637B2 (enExample) |
| KR (1) | KR20170003667A (enExample) |
| CN (1) | CN106536512B (enExample) |
| AP (1) | AP2016009554A0 (enExample) |
| AR (1) | AR100439A1 (enExample) |
| AU (1) | AU2015263049B2 (enExample) |
| CA (1) | CA2948582A1 (enExample) |
| EA (1) | EA201692298A1 (enExample) |
| MX (1) | MX2016014946A (enExample) |
| SG (1) | SG11201609311RA (enExample) |
| TN (1) | TN2016000491A1 (enExample) |
| TW (1) | TW201623288A (enExample) |
| UY (1) | UY36123A (enExample) |
| WO (1) | WO2015177646A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9403810B2 (en) | 2014-05-14 | 2016-08-02 | Novartis Ag | Carboxamide derivatives |
| TW201623288A (zh) | 2014-05-14 | 2016-07-01 | 諾華公司 | 甲醯胺衍生物 |
| CN108007916B (zh) * | 2017-03-16 | 2020-08-04 | 黑龙江八一农垦大学 | 希尔伯特黄法建立稻株氮含量的共聚焦显微拉曼测量模型 |
| CN110749687B (zh) * | 2019-04-04 | 2021-05-28 | 中山大学 | 一种日本血吸虫病早期诊断尿液生物标志物及筛选方法和应用 |
| CN110038012B (zh) * | 2019-05-30 | 2021-06-11 | 济南大学 | 具有1,2,3-三氮唑结构片段的生物碱化合物在制备促血管生成药物中的应用 |
| DE102020116104A1 (de) | 2020-06-18 | 2021-12-23 | Charité - Universitätsmedizin Berlin, Körperschaft des öffentlichen Rechts | Metamizolderivate zur Prävention und Therapie der pulmonalen Hypertonie |
| CN113636977B (zh) * | 2021-09-01 | 2022-12-20 | 温州大学 | 2-芳基苯并氮杂卓及其衍生物的合成方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7354722B1 (en) | 1999-06-11 | 2008-04-08 | Signal Pharmaceuticals | Modulators of Smurf and BMP/TGFβ signaling pathways |
| IL147005A0 (en) * | 1999-06-11 | 2002-08-14 | Univ New York State Res Found | Antagonists of bmp and tgfb signaling pathways |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| GB0312368D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel ureido- and amido-pyrazolone derivatives |
| WO2005030128A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
| US7291743B2 (en) | 2005-03-29 | 2007-11-06 | Geneblue Corporation | Isoxazole derivatives and methods of treating nitric oxide mediated diseases |
| EA200801108A1 (ru) * | 2005-10-31 | 2008-10-30 | Биолипокс Аб | Триазолы, пригодные для лечения воспалений |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| JP2011511756A (ja) | 2007-08-02 | 2011-04-14 | ナームローゼ・フエンノートチヤツプ・オルガノン | Ｔｒｐｖ１モジュレータとしての５−フェニル−イソオキサゾール−３−カルボキサミド誘導体 |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2011151361A1 (en) | 2010-06-03 | 2011-12-08 | Glaxo Group Limited | Novel compounds |
| TW201623288A (zh) | 2014-05-14 | 2016-07-01 | 諾華公司 | 甲醯胺衍生物 |
| US9403810B2 (en) | 2014-05-14 | 2016-08-02 | Novartis Ag | Carboxamide derivatives |
-
2015
- 2015-05-13 TW TW104115286A patent/TW201623288A/zh unknown
- 2015-05-13 US US14/711,693 patent/US9403833B2/en active Active
- 2015-05-14 MX MX2016014946A patent/MX2016014946A/es unknown
- 2015-05-14 UY UY0001036123A patent/UY36123A/es not_active Application Discontinuation
- 2015-05-14 CN CN201580038374.5A patent/CN106536512B/zh active Active
- 2015-05-14 TN TN2016000491A patent/TN2016000491A1/en unknown
- 2015-05-14 EA EA201692298A patent/EA201692298A1/ru unknown
- 2015-05-14 EP EP15774680.1A patent/EP3143014B1/en active Active
- 2015-05-14 WO PCT/IB2015/001539 patent/WO2015177646A1/en not_active Ceased
- 2015-05-14 JP JP2016567507A patent/JP6587637B2/ja active Active
- 2015-05-14 AP AP2016009554A patent/AP2016009554A0/en unknown
- 2015-05-14 CA CA2948582A patent/CA2948582A1/en not_active Abandoned
- 2015-05-14 AU AU2015263049A patent/AU2015263049B2/en not_active Ceased
- 2015-05-14 KR KR1020167034560A patent/KR20170003667A/ko not_active Withdrawn
- 2015-05-14 AR ARP150101497A patent/AR100439A1/es unknown
- 2015-05-14 SG SG11201609311RA patent/SG11201609311RA/en unknown
-
2016
- 2016-06-29 US US15/197,091 patent/US9931319B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515845A5 (enExample) | ||
| JP7592814B2 (ja) | Ｃｆｔｒ増強物質としてのピロロピリミジン | |
| EP2802577B1 (en) | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors | |
| US7151096B2 (en) | Cyclic compounds and compositions as protein kinase inhibitors | |
| AU2016323767B2 (en) | Antifungal compound process | |
| AU2015231234B2 (en) | Antifungal compound process | |
| NL1029726C2 (nl) | Triazolopyridinylsulfanylderivaten als remmers van p38-MAP-kinase. | |
| JP5567557B2 (ja) | テトラヒドロイソキノリンの製造方法 | |
| JP2020502103A (ja) | Ｃｆｔｒ増強物質としての二環式ヘテロアリール誘導体 | |
| MD3419978T2 (ro) | Derivaţi de pirazolo[1,5-a]pirazin-4-il | |
| JP2005517655A (ja) | Ｃｂ１アンタゴニストとしての５，６−ジアリール−ピラジン−２−アミド誘導体 | |
| JP2016512823A5 (enExample) | ||
| WO2014128655A1 (en) | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors | |
| US10023534B2 (en) | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK | |
| JP2009526037A (ja) | トリアゾロピリジン化合物 | |
| JP6284928B2 (ja) | ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス | |
| CN119212699A (zh) | Nlrp3抑制剂 | |
| TW201609694A (zh) | 用於製備３－（３－氯－１ｈ－吡唑－１－基）吡啶的方法（一） | |
| JP7178357B2 (ja) | オキサジアゾール一過性受容器電位チャネル阻害剤 | |
| WO2012036278A1 (ja) | グリシントランスポーター阻害物質 | |
| WO2011002408A1 (en) | Novel compounds for treatment of neurodegeneration associated with diseases, such as alzheimer's disease or dementia | |
| KR102000382B1 (ko) | 신규 시클로프로파벤조푸라닐 피리도피라진디온 | |
| CA3179333A1 (en) | Modulators of alpha-1 antitrypsin | |
| JP2013536798A5 (enExample) | ||
| JP2008520644A (ja) | オクタヒドロピロロ［３，４−ｃ］ピロール誘導体 |